The European Commission has granted marketing authorisation for Servier’s Valdoxan(R) /Thymanax(R) (agomelatine), the first melatonergic antidepressant for the treatment of adult patients with major depressive episodes. “There is still great scope for improved therapies to treat the devastating effects of depression,” said Professor Goodwin from Warneford Hospital, Oxford, United Kingdom.
Popularity: unranked [?]
Related posts:
- Novel Antidepressant Valdoxan(R), Receives EMEA CHMP Positive Opinion For Major Depressive Episodes
- Wyeth Europa Ltd Withdraws Its Marketing Authorisation Application For Ellefore For Major Depressive Disorder
- Wyeth Europa Ltd Withdraws Its Marketing Authorisation Application For Ellefore For Major Depressive Disorder
- Astrazeneca Submits Seroquel XR™ In Europe For The Treatment Of Major Depressive Disorder
- Wyeth’s Pristiq, A New Treatment For Major Depressive Disorder
Comments
No Responses to “Valdoxan(R) Granted Marketing Authorisation For The Treatment Of Major Depressive Episodes In Europe”